---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-116348"
form_type: "8-K"
ticker: "IMNM"
cik: "0001472012"
company_name: "Immunome Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:29:12.968610+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Immunome completes Morphimmune merger, $125M PIPE, Q3 net loss $4M

## Summary
- Completed merger with Morphimmune; concurrent $125M oversubscribed PIPE from Enavate Sciences, EcoR1 Capital, Redmile, Janus Henderson, Avidity, Woodline.
- Clay B. Siegall (ex-Seagen CEO) appointed Chairman & CEO; Bob Lechleider as CMO; Jean-Jacques Bienaimé (ex-BioMarin CEO) to board.
- Q3 collaboration revenue $4M from AbbVie; R&D and G&A each $4M; net loss $4M ($0.36 per share); cash $91M as of Sept 30.
- Cash runway extended into Q1 2026; expect IMM-ONC-01 IND guidance Q1 2024; 177Lu-FAP IND submission Q1 2025.

## SEC filing metadata
- accession: 0001104659-23-116348
- form_type: 8-K
- ticker: IMNM
- cik: 0001472012
- company_name: Immunome Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472012/000110465923116348/0001104659-23-116348-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472012/000110465923116348/tm2330142d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-116348
- JSON: https://secwatch.observer/filing/0001104659-23-116348.json
- Plain text: https://secwatch.observer/filing/0001104659-23-116348.txt

## Key facts
- Earnings Releases
  Immunome Inc. reported the third quarter ended September 30, 2023 results: revenue $4 million, net income Net loss ... was $4 million, or $(0.36) per share, EPS $(0.36) per share.
  - Period: the third quarter ended September 30, 2023
  - Revenue: $4 million
  - Net income: Net loss ... was $4 million, or $(0.36) per share
  - EPS: $(0.36) per share
  - Result: reported results
  source text: in Q1 2025. Financial Highlights · Collaboration Revenue: Collaboration Revenue from the Collaboration Agreement with AbbVie for the three months ended September 30, 2023 was $4 million. · Research and development (R&D) expenses: R&D expenses for the three months ended September 30, 2023 were $4 million. · General and administrative (G&A) expenses: G&A expenses
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472012/000110465923116348/0001104659-23-116348-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.